# Clinical trials recruiting in Japan: 1,216 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 1,216 trials recruiting or not yet recruiting with a site in Japan, as read on November 19, 2026.

## The full list

Clinical trials recruiting in Japan: 1,216 rows for $60.80, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 26 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/country/japan

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 1,216
- Recruiting or not yet: 1,216
- Read on: November 19, 2026

## Trials

The 25 newest of 1,216, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07931599 | A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 1,060 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931599) |
| November 12, 2026 | NCT07931547 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Type 2 Diabetes, Chronic Kidney Disease | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931547) |
| November 12, 2026 | NCT07931495 | A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Diabetes Mellitus, Type 2 | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07931495) |
| November 10, 2026 | NCT07929051 | A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Advanced Cancer | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929051) |
| November 10, 2026 | NCT07928258 | A Study of LY4336619 in Adult Participants With Advanced Solid Tumors | Eli Lilly and Company | Phase 1 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Neoplasms, Germ Cell and Embryonal, Carcinoma, Non-Small-Cell Lung, Stomach... | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07928258) |
| November 9, 2026 | NCT07926334 | A Study of BI 4015092, Alone or in Combination With Other Cancer Treatment, in Patients With Advanced Cancer That Has a KRAS G12D Mutation | Boehringer Ingelheim | Phase 1 | Not yet recruiting | Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926334) |
| November 9, 2026 | NCT07926321 | A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment | Boehringer Ingelheim | Phase 2 | Not yet recruiting | Idiopathic Pulmonary Fibrosis | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926321) |
| November 9, 2026 | NCT07926308 | Real-world Outcome of Zongertinib in Japan (J-HERZ) | Boehringer Ingelheim | Observational | Not yet recruiting | Non-small Cell Lung Cancer | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07926308) |
| November 5, 2026 | NCT07919405 | A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Hypertension, Obesity | 1,408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919405) |
| November 4, 2026 | NCT07917728 | Smartphone Enabled Detection of Cognitive Motor Dissociation in the ICU | Columbia University | Observational | Recruiting | Traumatic Brain Injury (TBI) Patients, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Cardiac Arrest (CA) | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917728) |
| November 4, 2026 | NCT07915219 | A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON) | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Bronchiectasis | 1,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915219) |
| November 3, 2026 | NCT07913568 | A Phase II Investigator-initiated Trial of Sacituzumab Tirumotecan Plus Pembrolizumab in Patients With Recurrent ovarIan Clear Cell... | National Cancer Center, Japan | Phase 2 | Not yet recruiting | Ovarian Clear Cell Carcinoma | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913568) |
| November 3, 2026 | NCT07913347 | Safety, Dosage, and Microbiome Engraftment Study of MGT-006 for Ulcerative Colitis (ROOT Study) | Metagen Therapeutics, Inc. | Phase 1/2 | Recruiting | Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07913347) |
| October 30, 2026 | NCT07906106 | A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB) | Juro Sciences Inc. | Phase 2 | Recruiting | Participants With Underactive Bladder (UAB) | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906106) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 20, 2026 | NCT07884318 | Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease | Metcela Inc. | Observational | Recruiting | Single Ventricle, Hypoplastic Left Heart Syndrome (HLHS) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07884318) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 19, 2026 | NCT07881432 | A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity | 2,115 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881432) |
| October 14, 2026 | NCT07872722 | Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction... | National Cancer Center, Japan | Phase 2 | Recruiting | CLDN18.2-Positive Gastric Cancer, CLDN18.2-Positive Gastroesophageal Junction Adenocarcinoma | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872722) |
| October 13, 2026 | NCT07872449 | Risankizumab for Refractory Perianal Fistulizing Crohn's Disease | Sponsor not shown (see the record) | Phase 4 | Recruiting | Crohn Disease, Perianal Fistula, Perianal Fistula Due to Crohn's Disease, Perianal Crohn's Disease | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872449) |
| October 13, 2026 | NCT07871214 | A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage... | Bristol-Myers Squibb | Phase 2 | Not yet recruiting | Early-Stage Non-Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871214) |
| October 13, 2026 | NCT07870837 | Head-to-Head (H2H) Comparison of Ambulatory Cardiac ECG Monitors in Japan | iRhythm Technologies, Inc. | Not applicable | Not yet recruiting | Atrial Fibrillation (AF), Atrial Flutter, Supraventricular Tachycardia (SVT), Ventricular Tachycardia (VT), Ventricular... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870837) |
| October 9, 2026 | NCT07867080 | A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME). | 4D Molecular Therapeutics | Phase 3 | Recruiting | Diabetic Macular Edema (DME) | 514 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07867080) |
| October 7, 2026 | NCT07862088 | Management and Outcomes of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula | Tokyo University | Observational | Recruiting | Acute Pancreatitis, Pancreatic Fluid Collection, Postoperative Pancreatic Fistula | 5,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862088) |
| October 6, 2026 | NCT07861100 | A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular... | Novo Nordisk A/S | Phase 3 | Not yet recruiting | Cardiovascular Risk, Obesity | 8,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07861100) |

## Sites with the most of these trials

Sites as the records name them, organizations only.

| Site | City | Trials |
| --- | --- | --- |
| National Cancer Center Hospital East | Kashiwa | 153 |
| National Cancer Center Hospital | Tokyo | 151 |
| Hokkaido University Hospital | Sapporo | 101 |
| Shizuoka Cancer Center | Nagaizumi-cho,Sunto-gun | 95 |
| Okayama University Hospital | Okayama | 85 |
| Kyushu University Hospital | Fukuoka | 83 |
| Kansai Medical University Hospital | Hirakata | 81 |
| Kindai University Hospital | Sakai | 81 |
| Tohoku University Hospital | Sendai | 77 |
| Juntendo University Hospital | Bunkyo | 66 |
| Kanagawa Cancer Center | Yokohama | 64 |
| Saitama Medical University International Medical Center | Hidaka | 60 |
| Osaka International Cancer Institute | Osaka | 60 |
| Kyoto University Hospital | Kyoto | 58 |
| The Cancer Institute Hospital of JFCR | Koto | 57 |
| The University of Osaka Hospital | Suita | 57 |
| Nagoya University Hospital | Aichi, Nagoya | 56 |
| Kurume University Hospital | Kurume | 54 |
| Tokyo Medical University Hospital | Shinjuku | 54 |
| Hiroshima University Hospital | Hiroshima | 54 |
| Cancer Institute Hospital of JFCR | Koto | 50 |
| National Hospital Organization Kyushu Cancer Center | Fukuoka | 49 |
| Aichi Cancer Center | Nagoya | 46 |
| Fukushima Medical University Hospital | Fukushima | 43 |
| Keio University Hospital | Shinjuku-ku | 43 |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 118 |
| Phase 1/2 | 109 |
| Phase 2 | 180 |
| Phase 2/3 | 42 |
| Phase 3 | 506 |
| Phase 4 | 28 |
| Not applicable | 66 |
| Observational | 167 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Carcinoma, Non-Small-Cell Lung | 90 |
| Neoplasms | 58 |
| Breast Neoplasms | 44 |
| Colorectal Neoplasms | 37 |
| Ovarian Neoplasms | 35 |
| Multiple Myeloma | 34 |
| Obesity | 32 |
| Stomach Neoplasms | 30 |
| Neoplasm Metastasis | 29 |
| Prostatic Neoplasms | 28 |
| Lung Neoplasms | 27 |
| Recurrence | 26 |
| Endometrial Neoplasms | 26 |
| Small Cell Lung Carcinoma | 24 |
| Overweight | 24 |
| Squamous Cell Carcinoma of Head and Neck | 24 |
| Diabetes Mellitus, Type 2 | 22 |
| Colitis, Ulcerative | 22 |
| Triple Negative Breast Neoplasms | 20 |
| Alzheimer Disease | 20 |
| Crohn Disease | 20 |
| Urinary Bladder Neoplasms | 19 |
| Carcinoma, Hepatocellular | 17 |
| Pancreatic Neoplasms | 17 |
| Heart Failure | 15 |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 92 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 70 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 54 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 50 |
| [Novartis Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/novartis-pharmaceuticals) | 49 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 46 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 45 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 41 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 36 |
| [Takeda](https://specstream.ai/data/clinical-trials/company/takeda) | 36 |
| [Janssen Research & Development, LLC](https://specstream.ai/data/clinical-trials/company/janssen-research-and-development-llc) | 32 |
| [Daiichi Sankyo](https://specstream.ai/data/clinical-trials/company/daiichi-sankyo) | 22 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 21 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 17 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 16 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 16 |
| [Ono Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/ono-pharmaceutical-co-ltd) | 14 |
| National Cancer Center, Japan | 14 |
| [Bayer](https://specstream.ai/data/clinical-trials/company/bayer) | 13 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 12 |
| [Otsuka Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/otsuka-pharmaceutical-co-ltd) | 11 |
| [Astellas Pharma Global Development, Inc.](https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc) | 11 |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 11 |
| [Alexion Pharmaceuticals, Inc.](https://specstream.ai/data/clinical-trials/company/alexion-pharmaceuticals-inc) | 8 |
| [Incyte Corporation](https://specstream.ai/data/clinical-trials/company/incyte-corporation) | 8 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Produce wholesalers in the United States](https://specstream.ai/data/businesses/produce-wholesalers/united-states)
- [Retaining wall suppliers in the United States](https://specstream.ai/data/businesses/retaining-wall-suppliers/united-states)
- [Social security law firms in the United States](https://specstream.ai/data/businesses/social-security-law-firms/united-states)
- [Tax law firms in the United States](https://specstream.ai/data/businesses/tax-law-firms/united-states)
- [Turkish restaurants in the United States](https://specstream.ai/data/businesses/turkish-restaurants/united-states)
- [West African restaurants in the United States](https://specstream.ai/data/businesses/west-african-restaurants/united-states)
